• PD-L1/PD-1 mediated CD8 T-cell dysfunction develops with CLL in different organs, and similarities to aging-related immune defects exist.
The corresponding binding partner of PD-L1, PD-1 (CD279), is a major inhibitory receptor associated with T-cell exhaustion, a state of functional hypo-responsiveness caused by chronic infections [8] [9] [10] [11] . Binding of PD-1 to PD-L1 and PD-L2 results in repressed T-cell receptor signaling, proliferation and motility [12] [13] [14] [15] . However, recent evidence suggests that this is neither an irreversible, terminal differentiation state nor an unresponsive T-cell state; instead, T cells with an exhaustion phenotype represent a heterogeneous population, in which subsets are, despite PD-1 expression, able to maintain and exert certain effector functions 16, 17 . CD8 + T cells from CLL patients exhibit some features of exhaustion such as increased PD-1expression, but conflicting data exists on its functional impact: while
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From we have described impaired T-cell proliferation and cytotoxicity with maintained IFN-γ /TNF-α production 4 , increased PD-1 expression on proliferating compared to nonproliferating T cells, along with impaired IFN-γ/IL-4 production, has been reported by others 18 . Interestingly, this was also observed after stimulation of T cells from healthy controls, albeit at a lower degree, suggesting a somewhat constrained physiological reaction in CLL T cells. PD-1 + T cells in CLL therefore appear to be a highly heterogeneous population, in which certain effector-functions might be maintained despite PD-1 expression. However, the functional characteristics of these populations and how distinct states of dysfunction develop in the context of advancing CLL remain poorly understood. This is further complicated by the finding that PD-1 expression plays an important role in T-cell homeostasis in healthy older humans 19 . This needs to be taken into account when interpreting PD-1 and immune function in CLL, as it is predominantly a disease of the elderly. Moreover, the majority of studies on PD-L1/PD-1 in CLL have been conducted in peripheral blood (PB). For CLL cells, characteristic tissue/compartment-specific gene signatures 20,21 , CD38 expression patterns 22, 23 , proliferation 24 , and apoptotic regulation mechanisms 25, 26 are now well recognized. The importance of different microenvironments on T-cell defects, their association with PD-1 expression and their contribution to the interactions between PD-L1 expressing CLL and PD-1 expressing T cells, are in contrast still poorly understood.
The majority of these questions can only be partly addressed in human CLL. As development of CLL in transgenic Eμ-TCL1 mice 27 is associated with global T-cell defects very similar to those observed in human patients 28, 29 , this mouse model offers a powerful preclinical platform to investigate T-cell directed questions in the For personal use only. on September 24, 2017. by guest www.bloodjournal.org From context of aggressive CLL. The aims of the current study were therefore to use the Eμ-TCL1 model to examine the longitudinal development of T-cell dysfunction in the context of advancing CLL, to identify the impact of different microenvironments on Tcell defects and PD-L1, PD-L2 and PD-1 expression, and to elaborate the functional impact of PD-1 expression on T-cell effector function.
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Methods and Materials

Mice and in vivo procedures
All animal work was carried out following local ethical regulations. Disease-status was monitored by physical examination and hematology testing. Aging Eµ-TCL1 mice were euthanized at 3, 6 and 12 months of age, or when fully leukemic (for initial characterization of PD-L1, see Figure 3A -C). Age-matched wild-type (WT) littermates and WT mice from commercial suppliers served as controls. In adoptive transfer (AT) experiments, young CLL-free mice received 4x10 7 frozen splenocytes from leukemic Eµ-TCL1 donors (%CD19 + CD5 + CLL cells routinely confirmed >95%)
or an equal dose of WT spleen B cells by i.v. injection. AT and leukemic Eµ-TCL1 mice were euthanized once they exhibited WBC counts >100 WBC/hpf (40x objective), >90% lymphocytes CD19 + CD5 + CLL cells, and/or spleen size >3cm compressing other organs.
Tissue preparation
PB was collected in EDTA-coated Eppendorf tubes by cardiac puncture. Spleen single-cell suspensions were prepared using an automated tissue dissociator (Miltenyi, UK) per manufacturer's recommendations. Lymph nodes (LN) were dissociated manually. Femurs were flushed with FACS buffer. Although the peritoneal cavity is an area of interest in mice, this was not examined here since we focused on compartments of particular relevance in human disease.
Immunophenotyping by multicolor flow cytometry
Surface staining was performed in PBS/2% FCS for 30min at 4°C following standard procedures using anti-CD5, CD19, CD3, CD4, CD8, CD44, CD62L, PD-L1/2, PD-1, KLRG-1, LAG-3 and 2B4 antibodies (all from eBioscience or Biolegend, UK). CCR7 staining was performed at 37°C for 20 minutes. Fluorescence-minus-one (FMO), internal negative and/or isotype controls were always included. Gating strategies and definition of populations are summarized in Suppl. 
Functional flow cytometry assays
Flow cytometry-based functional assays were performed on fresh T cells±Phorbol-12-Myristrate-13-Acetate (40.5µM)/Ionomycin (670µM) mitogenic stimulation for 6h in the presence of Brefeldin A (5.3mM)/Monensin (1mM, eBioscience, UK) for the last 5h. Effector-cell activity was assessed by CD107a surface expression 31 and intracellular Granzyme B (GrB), IL-2, IL-4 and IFN-γ levels in stimulated CD4 + and CD8 + cells (Suppl. Fig. 1C The synapse area was reported as the area of T-cell F-actin immune synapses (μm  2 ) value.
Statistical considerations
To account for batch/litter effects, phenotyping experiments were conducted at least twice with a minimum of 5 matched mice/group. Functional experiments and ANs were determined once in ≥ 6 mice/group (aging mice) and twice in AT mice (≥ 4 mice/group). As mice showed no evidence for unexpected litter effects (p>.05 for each), experimental groups were analyzed and depicted together. Data sets were subjected to normality testing using the 
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Developing CLL is associated with specific T-cell subsets changes in spleen,
PB, BM and LNs
To determine CLL load/development, PB and single-cell suspensions from BM, LN and spleens of 3, 6 and 12 month old Eµ-TCL1, aged-matched WT, and AT mice were stained for CD19/CD5. Increasing numbers of CD19 + CD5 + CLL cells were detected in spleen, PB, and BM, but not yet in LN, from 6 month old Eµ-TCL1 mice, while 3 month old Eµ-TCL1 and all WT mice were CLL-free (Suppl. Fig. 2A-C 1C ) and effector/memory differentiation (Suppl. Tables1+2). Some similarities in T-cell subset changes were also noted in aging WT mice (Fig. 1A-H , Suppl. Table1). ANs of virtually all cell-subsets increased in aging Eµ-TCL1 and after AT, but were largely stable in aging WT mice (Suppl. Fig. 3A) . ANs of cells in other organs followed similar patterns (Suppl. Fig. 3B-D) . Altogether, both longitudinal and direct comparison of aging Eµ-TCL1, WT and AT mice led to characterization of CLL-and aging-specific T-cell phenotypes and highlighted differences between CLL-affected compartments and aging Eµ-TCL1 and AT mice (visualized in Fig. 1I ).
Developing CLL leads to characteristic functional changes in T-cell intracellular cytokines and effector function
We next investigated functional T-cell changes using splenocytes from 3, 6 and 12 month old Eµ-TCL1, WT and AT mice. Typical functional T-cell changes are summarized in Figure 2A . WT mice only exhibited a non-significant trend (Fig. 2D) . GrB ratios decreased nonsignificantly in WT mice but were stable in aging Eµ-TCL1 (Fig. 2E ). Developing CLL in aging Eµ-TCL1 mice led to increased IFN-γ ratios, which was however not significant in AT mice (Fig. 2F ). Immune synapse formation was significantly impaired in 12 month old Eµ-TCL1 and in AT mice, but not yet in 6 month old TCL1 mice ( Fig. 2G ). Of note, T-cell proliferation was increased with developing CLL and after AT, as evidenced by increased ki-67 ratios among CD8 + CD44 + cells (Fig. 2H ), which was confirmed by in vivo EdU incorporation in CD8 + and CD4 + cells (Fig. 2I ).
Since CD4 proliferation was increased, but the CD4 + /CD8 + ratio fell, there must be increased CD4 cell death, although cell-survival studies were not performed.
High PD-L1/PD-L2 expression develop in the context of advancing disease and
PD-L1 shows tissue-specific distribution
As PD-L1/PD-1 are important mediators of T-cell dysfunction in human CLL, we next assessed PD-L1 expression on spleen CLL cells from fully leukemic Eµ-TCL1 (n=8, median age 47 weeks; range 39.4-57.1) and AT mice (n=12), and on CD19 + B cells from age-matched WT mice (n=12 total). While the percentages of PD-L1 + CLL/B cells were higher in leukemic than in WT mice (Fig. 3A) but high in both groups, we observed more pronounced changes in corrected MFIs (Fig. 3B) and ANs (Fig. 3C ).
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Increased PD-L1 developed alongside advancing CLL, and could also be detected on CLL cells from other organs (Fig. 3D left) . However, in 12 month old Eµ-TCL1 mice, PD-L1 expression was higher in spleen (corrected MFI 4037±428.3 SD), LN (2632±736.5) and BM (2549±864) than in PB (1886±425.5), suggesting tissuespecific expression. A similar pattern was detected for PD-L2 expression (Fig. 3D right), but organ-specific expression was less apparent. This was again recapitulated in AT mice. (Fig. 3H ). PD-1 induction by AT was confirmed by another experiment, in which recipient mice were randomized to AT with CLL or normal B cells (n=9 each). This led to significantly higher expression of PD-1 in CLL-cell versus healthy B-cell recipients (Suppl. Fig. 4B ), both on CD44 + (Suppl. Fig. 4C ) and on CD44 -CD3 + CD8 + cells (Suppl. Fig. 4D ). Similar patterns were observed for other inhibitory T-cell receptors including KLRG-1, 2B4 and LAG-3 (Suppl. Fig. 5A-D) . 4C right). Moreover, the significantly increased IFN-γ production associated with advanced CLL could be attributed to both PD-1 subsets (p=1.0, Fig. 4C left).
EdU ratios were comparable between PD-1 high and PD-1 low cells in aging WT mice ( Fig. 4D left) . CLL-induced increased T-cell proliferation was found to be attributed to both PD-1 subsets, with the PD-1 high ratio being significantly higher than the PD-1 low For personal use only. on September 24, 2017. by guest www.bloodjournal.org1 5 ratio (6 month p=.0087, 12 month p=.0317, Figure 4D right), suggesting that increased T-cell proliferation is predominantly accounted for by PD-1 high cells.
The effect of PD-1 expression on immune synapse was further examined in AT mice.
Compared to normal CD8 + T cells, the ability of CLL CD8 + T cells to form synapses with healthy B cells as antigen-presenting cells was significantly impaired (p<.0001).
However, PD-1 low CD8 + T cells formed larger synapses than PD-1 high CD8 + T cells (p<.0001), indicating that the impaired ability of CD8 + T cells seems to be promoted by the PD-1 high subset ( Fig. 5A-B ).
Discussion
We used the Eμ-TCL1 mouse model and aged-matched WT mice as a preclinical platform to examine patterns of T-cell dysfunction in the context of developing CLL in different microenvironments and in direct comparison to aging-related T-cell defects, with a focus on PD-1/PD-L1/PD-L2, which are a major immunosuppressive mechanism in CLL 4, 7, 18 . Previous studies in Eμ-TCL1 mice demonstrated that molecular T-cell defects and subset changes can be modeled in leukemic mice 28, 29, 32 , but have failed to take full advantage of the availability of different microenvironments. In CLL patients, T-cell defects and associations with aggressive disease/ poor outcome have been extensively characterized 3, 4, 6, 18, [33] [34] [35] [36] [37] homing of CLL cells to other organs. As a result, induction of LN involvement by AT did not fully mirror LN involvement in aging mice.
The development of CLL also led to characteristic changes in T-cell cytokines and effector function, which were distinct from aging WT mice. This was even more pronounced after AT, most likely because of the increased immunosuppressive effect exerted by synchronized onset of antigenic stimulation. Interestingly, in aging Eµ-TCL1 mice, significant functional changes were not apparent until later stages of CLL. Immune synapse formation was actually improved in 6 month old Eµ-TCL1 mice, indicating that cytotoxic functions might be maintained as a result of compensation by "over-functioning" immune synapses in early stages of antigenencounter with CLL. Surprisingly, CD8 + T-cell proliferation increased with developing CLL and after AT, in contrast to our human work, which found a proliferative defect in PB CLL T cells 4 . These discrepancies can potentially be attributed to a compartment-specific effect, as described for CLL cells
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, or by different dynamics in humans where patients may have had the disease for a long period before they are diagnosed and studied. Further studies will be needed to address the effect of the microenvironment on T-cell proliferation in vivo, and include subsets of CD4 + T cells to further understand their importance for CLL-cell migration, survival and proliferation 22, 42, 43 .
Inhibition of the PD-1/PD-L1 axis is emerging as a very attractive therapeutic target in cancer [44] [45] [46] . To understand fully the potential of such approaches in CLL, we characterized mechanisms of PD-1/PD-L1 mediated T-cell dysfunction in the Eμ-TCL1 model. We found that highly increased PD-L1 as in human CLL 7 is characteristic of murine CLL cells, can be detected in all organs, but is highest in
spleen, suggesting a modulating effect of the microenvironment. This is an important finding, as tissue-specific differences selectively support the persistence of PD-L1 mediated defects in infection models 47 , and might explain the tumor-protecting effects of microenvironmental niches. Similar patterns but less tissue-specificity were found for PD-L2, therefore verifying its relevance as another inhibitory molecule in CLL 48, 49 . In solid malignancies, PD-L1 appears to be the dominant negative molecule, with PD-L2 expressed in only a minority of patients [50] [51] [52] . 
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